These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27448700)

  • 41. [The impact of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention].
    Xu XR; Li KB; Wang P; Xu L; Liu Y; Yang ZS; Yang XC
    Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):932-936. PubMed ID: 27916047
    [No Abstract]   [Full Text] [Related]  

  • 42. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
    Choudhry NK; Levin R; Winkelmayer WC
    Heart; 2007 Aug; 93(8):945-51. PubMed ID: 17344334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention.
    Yadav M; Généreux P; Giustino G; Madhavan MV; Brener SJ; Mintz G; Caixeta A; Xu K; Mehran R; Stone GW
    Can J Cardiol; 2016 Feb; 32(2):226-33. PubMed ID: 26341303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy.
    Tentzeris I; Farhan S; Freynhofer MK; Rohla M; Jarai R; Vogel B; Baumgartner-Parzer S; Nürnberg M; Geppert A; Wessely E; Wojta J; Huber K; Kautzky-Willer A
    Am J Cardiol; 2017 Sep; 120(5):747-752. PubMed ID: 28734463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
    Bangalore S; Fayyad R; Kastelein JJ; Laskey R; Amarenco P; DeMicco DA; Waters DD
    Am J Med; 2016 Apr; 129(4):384-91. PubMed ID: 26551986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes.
    Tentzeris I; Rohla M; Jarai R; Farhan S; Freynhofer MK; Unger G; Nürnberg M; Geppert A; Wessely E; Wojta J; Huber K
    Am J Cardiol; 2014 Apr; 113(7):1099-104. PubMed ID: 24462073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
    Japaridze L; Sadunishvili M
    Kardiol Pol; 2017; 75(8):770-778. PubMed ID: 28553847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome.
    Matsushita K; Hibi K; Komura N; Akiyama E; Maejima N; Iwahashi N; Tsukahara K; Kosuge M; Ebina T; Sumita S; Umemura S; Kimura K
    Circ J; 2016 Jun; 80(7):1634-43. PubMed ID: 27264413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
    Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
    Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of atorvastatin on serum omentin-1 in patients with coronary artery disease.
    Chen Q; Shang X; Yuan M; Liang L; Zhong X
    Coron Artery Dis; 2017 Jan; 28(1):44-51. PubMed ID: 27749321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
    Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
    J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Berwanger O; de Barros E Silva PGM; Dall Orto FTC; de Andrade PB; de Castro Bienert IR; Bosso CE; Mangione J; Polanczyk CA; Sousa A; Kalil R; de Moura Santos L; Sposito AC; Rech RL; Sousa ACS; Baldissera F; Nascimento BR; de Andrade Jesuíno I; Santucci EV; Damiani LP; Laranjeira LN; Borges de Oliveira JA; Giraldez RR; Cavalcanti AB; Pereira SB; Mattos LA; Armaganijan LV; Guimarães HP; Sousa JE; Alexander JH; Granger CB; Lopes RD
    Am Heart J; 2018 Apr; 198():129-134. PubMed ID: 29653634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE ACS randomized controlled trial: Bioactive versus everolimus-eluting stents in elderly patients.
    Nammas W; de Belder A; Niemelä M; Sia J; Romppanen H; Laine M; Karjalainen PP
    Eur J Intern Med; 2017 Jan; 37():43-48. PubMed ID: 27499178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
    Ito T; Fujita H; Tani T; Ohte N
    Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.